Novartis is stepping on the cGAS. Three years after securing an option on an IFM Therapeutics subsidiary, the Swiss drugmaker has accelerated into the deal and paid $90 million upfront for small ...
Novartis is handing over $310 million up front to acquire IFM Therapeutics’ inflammation-centered subsidiary, IFM Tre. The deal includes up to $1.265 billion in milestones and gives Novartis access to ...
Milestone marks the third major acquisition for an IFM Therapeutics subsidiary in the past seven years The acquisition provides Novartis with full rights to IFM Due's portfolio of STING antagonists, ...
IFM Therapeutics LLC, an innate immunity specialist that's quickly sparked major deals with big pharma, is stoking the generative fire at its heart with $55.5 million in new financing led by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results